Safety
In terms of safety, the data suggest that the single-dose AmBisome regimen has advantages over current guidance. In the Hamill et al trial, 23.3% of those on 3 mg/kg/d and 41% of those on 6 mg/kg/d AmBisome developed hemoglobin levels ≤8 g/dL [